The present application describes novel hydantoin derivatives of formula (I): ##STR00001## or pharmaceutically acceptable salt or prodrug forms thereof, wherein A, B, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.11, and n are defined in the present specification, which are useful as inhibitors of matrix metalloproteinases (MMP), TNF-.alpha. converting enzyme (TACE), aggrecanase, or a combination thereof.